Sarcoma Study of MORAb-004 Utilization: Research & Clinical Evaluation

Updated 04/19/2024

Status Completed

Clinical Trial Summary

This study is being done to see if MORAb-004 increases the effectiveness of the chemotherapies gemcitabine and docetaxel in people with metastatic Soft Tissue Sarcoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01574716
Study type	Interventional
Source	Morphotek
Contact
Status	Completed
Phase	Phase 2
Start date	August 7, 2012
Completion date	August 2, 2016

See also
	Status	Clinical Trial	Phase
	Active, not recruiting	`NCT03670069` - Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas	Phase 1
	Recruiting	`NCT05075993` - Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors	Phase 1
	Suspended	`NCT03793361` - Phase II Study of Regorafenib as Maintenance Therapy	Phase 2
	Completed	`NCT03009201` - Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery	Phase 1
	Withdrawn	`NCT03397186` - Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma	Phase 2
	Recruiting	`NCT03965234` - Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases	Phase 1/Phase 2
	Recruiting	`NCT04028063` - Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas	Phase 2
	Active, not recruiting	`NCT04200443` - Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma	Phase 2
	Recruiting	`NCT05711615` - Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma	Phase 1
	Active, not recruiting	`NCT01514188` - Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma	Phase 2
	Completed	`NCT02500797` - Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery	Phase 2
	Recruiting	`NCT03138161` - SAINT:Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma	Phase 1/Phase 2
	Active, not recruiting	`NCT03660930` - Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas	Phase 1/Phase 2